Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Minerva Neurosciences, Inc

NERV

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Last trade $2.12
Day change -$0.08 (-3.64%)
Day range $2.03 – $2.34
Volume 86,304
Market cap $110M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$109.64M
Price / earnings
—
Price / book
-1.12×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.14×

Profitability

Earnings per share
-$5.95
Return on assets
-301.96%
Return on equity
304.3%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0×
Current ratio
33.02×
Quick ratio
33.02×
Cash ratio
8×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$31.4M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NERV, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$4.28M$3.45M$11.42M$2.81M$1.92M$2.08M$2.54M$2.54M
Research and development$5.16M$7.19M$5.25M$2.17M$925.38K$1.3M$1.36M$1.98M
Total operating expenses$9.43M$10.64M$16.67M$4.98M$2.84M$3.37M$3.9M$4.52M
Operating income-$9.43M-$10.64M-$16.67M-$4.98M-$2.84M-$3.37M-$3.9M-$4.52M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes$100.75M$17.47M-$125.4M-$283.67M-$2.74M-$3.26M-$3.75M-$4.27M
Income taxes$0$0$0$0$0$0$0$0
Net income$100.75M$17.47M-$125.4M-$283.67M-$2.74M-$3.26M-$3.75M-$4.27M
Net income attributable to common shareholders$95.66M$16.65M-$125.4M-$283.67M-$2.74M-$3.26M-$3.75M-$4.27M
EBITDA-$9.43M-$10.64M-$16.67M-$4.98M-$2.84M-$3.37M-$3.9M-$4.52M
Basic earnings per share$1.94$0.36-$2.86-$25.45-$0.36-$0.43-$0.50-$0.56
Diluted earnings per share-$0.19-$0.14-$2.86-$25.45-$0.36-$0.43-$0.50-$0.56

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates

Minerva Neurosciences reported Q3 2026 financial results with R&D expenses of $5.2M (up from $0.9M YoY) driven by the ongoing Phase 3 C19 trial of roluperidone for schizophrenia negative symptoms. Topline efficacy data from Phase A is expected in 2H 2027. The company maintains $77M in cash and positions roluperidone as the only late-stage candidate targeting negative symptoms. A KOL event is scheduled for November 12, 2026.

GlobeNewswire Inc.

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

Minerva Neurosciences announced participation in two upcoming investor conferences (Wells Fargo Healthcare Conference on September 8 and Cantor Global Healthcare Conference on September 9, 2026). The company is conducting a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia, with topline efficacy data expected in the second half of 2027. The company has also established a Scientific Advisory Board of leading experts in psychiatry and neuroscience.

GlobeNewswire Inc.

Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum

Minerva Neurosciences announced that CEO Remy Luthringer will present at The Stifel 2026 Virtual CNS Forum on March 18, 2026. The company is a clinical-stage biopharmaceutical firm focused on CNS disorder treatments, currently initiating a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia.

GlobeNewswire Inc.

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates

Minerva Neurosciences reported FY2025 results with a net loss of $293.4 million (primarily due to $321.5 million in non-cash warrant and preferred stock issuance expenses). The company secured $80 million in gross proceeds from a private placement in October 2025 and plans to initiate a confirmatory Phase 3 trial for roluperidone for negative symptoms of schizophrenia in Q2 2026, with topline data expected in 2H 2027. Cash position improved to $82.4 million from $21.5 million year-over-year.

Benzinga

Minerva Stock Rises After Securing $200M for Schizophrenia Drug Trial

Minerva Neurosciences secured a $200 million funding agreement to support its Phase 3 trial for roluperidone, a drug targeting negative symptoms of schizophrenia. The funding includes immediate $80 million and potential additional tranches, with investors like Vivo Capital and Janus Henderson participating.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 21, 20221-for-8reverse split